Mei Ching Ong, Region Head for Asia and Eastern Europe at The Max Foundation, shared a post on LinkedIn by The Max Foundation, adding:
“Twenty-five years ago, the first TKI was approved for Chronic Myeloid Leukemia – marking a turning point that would impact lives around the world.
But breakthroughs alone aren’t enough. True impact comes from human connection – when people come together to ensure life-saving treatments reach those who need them most.
This isn’t just a story of science; it’s a story of humanity in action.
Join us to hear these powerful stories – dial in to join us webinar next week!
When: Monday, May 11, 08:30 AM Pacific Time
Register.”
Quoting The Max Foundation’s post:
“Join us for a webinar on May 11 about the 25th anniversary of an innovative medication for chronic myeloid leukemia (CML)!
Experts will discuss the birth of targeted therapy and the ongoing work to ensure people living with CML have access to the treatment they need. You’ll hear from:
- Brian Druker, president of the OHSU Knight Cancer Institute and the lead developer of the medication
- Jan Geissler, cofounder of the CML Advocates Network
- Pat Garcia-Gonzalez, Max CEO
- Paula Boultbee, Max board member
- Dr. Jerry Radich, Max board member, professor and clinical researcher at Fred Hutch
Other articles about The Max Foundation on OncoDaily.